XTX Topco Ltd Buys 3,911 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

XTX Topco Ltd grew its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 27.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,370 shares of the biopharmaceutical company’s stock after purchasing an additional 3,911 shares during the period. XTX Topco Ltd’s holdings in Halozyme Therapeutics were worth $1,172,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Bessemer Group Inc. grew its stake in shares of Halozyme Therapeutics by 62.9% during the first quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 207 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in Halozyme Therapeutics during the 4th quarter worth $29,000. Park Place Capital Corp increased its holdings in Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 182 shares in the last quarter. UMB Bank n.a. raised its position in Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 960 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Halozyme Therapeutics by 46.3% during the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 438 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Performance

HALO stock opened at $59.02 on Friday. The firm has a market cap of $7.27 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 0.40 and a beta of 1.17. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The stock has a 50-day moving average price of $55.30 and a 200-day moving average price of $57.70. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $70.50.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.13. The firm had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The company’s revenue was up 35.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.79 earnings per share. As a group, equities research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Analyst Ratings Changes

HALO has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price objective for the company. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a report on Thursday, May 29th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a report on Wednesday, May 7th. Finally, Leerink Partnrs downgraded Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $62.70.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $56.43, for a total value of $1,128,600.00. Following the completion of the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at approximately $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 60,000 shares of company stock valued at $3,262,400 in the last ninety days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.